Answers are grounded in this paper and cite their sources.
This case demonstrates that with early multidisciplinary intervention, epoprostenol therapy, and planned delivery, successful maternal and fetal outcomes can be achieved in severe pulmonary arterial hypertension during pregnancy.
Successful maternal and fetal outcomes have been demonstrated with an aggressive team management approach, early delivery, and detailed postpartum care.Pulmonary arterial hypertension (PAH) is a rare disease characterized by progressive dyspnea and exercise intolerance, with death due to right-sided heart failure. Before 1985, median survival was 2.8 years from diagnosis, with no known effective therapies.1 Epoprostenol was the first medication approved in 1996, and since that time, significant advances in treatment have occurred, including the addition of multiple medication therapies leading to improved management of symptoms.2–4 The prognosis of PAH, although improved, remains poor, with a 15% mortality during the first year of treatment.5,6The pathophysiology of PAH includes complex endothelial dysfunction leading to remodeling of the wall of the pulmonary artery, causing exaggerated vasoconstriction and impaired vasodilatation. This vascular injury can occur in an idiopathic form or in association with other disease states. Normally, the pulmonary circulation is a low-pressure system with low vascular resistance as blood leaves the right side of the heart and goes to the lungs. Mean pulmonary artery pressure (PAP) is normally from 15 to 20 mm Hg, with a pulmonary capillary wedge pressure of 8 to 12 mm Hg and pulmonary vascular resistance of 100 to 250 dynes • sec • cm−5 with a calculation of less than 3 Wood units. Wood units are a calculated pulmonary vascular pressure that is derived by subtracting the pulmonary capillary wedge pressure from the PAP and dividing by the cardiac output. Conversely, patients with PAH have an elevated PAP (mean, >25 mm Hg), with normal pulmonary capillary wedge pressure (<15 mm Hg), and elevated pulmonary vascular resistance (≥ 3 Wood units) without left-sided heart disease, lung disease, or thromboembolic disease.4,6Diagnosis of PAH may be delayed because of the subtlety and nonspecificity of patients’ symptoms. The symptoms most commonly reported in nonpregnant patients are exertional dyspnea, fatigue, chest pain, syncope, and lower extremity edema.2,4 A comprehensive workup for all PAH patients includes pulmonary function testing, connective tissue serology, testing to rule out chronic thromboembolic disease, echocardiography, and catheterization of the right side of the heart. The catheterization with vasodilator testing is the reference standard for confirming PAH and for determining its severity.4,6Pregnancy has been contraindicated in women with known PAH because of the high mortality rate during the pregnancy itself.7 Normal physiological changes of pregnancy include a 50% increase in blood volume, an increase of 30% to 50% in cardiac output, and a decline in systemic vascular resistance.8–10 During labor, cardiac output increases by 50% with increases in blood volume of 300 to 500 mL with each contraction.10 Immediately after delivery, maternal blood volume is additionally increased approximately 500 mL as a result of autotransfusion from the involuting uterus and the sudden cessation of obstruction of the inferior vena cava by the gravid uterus. Cardiac output remains elevated for 48 hours after delivery with gradual return over 2 to 12 weeks to non-pregnant values. Pregnant patients with PAH have a limited ability to cope with the sudden increase in blood volume and cardiac output, which can lead to rapid onset of right ventricular failure and cardiac arrest.8,9,11 Previous case studies of pregnant PAH patients have reported on maternal mortality rates from 30% to 56%, with premature delivery occurring in more than 50% of patients, and the highest risk of death in the first 10 days after delivery.12–14 Recent data on a series of 37 pregnant patients with PAH have demonstrated successful maternal and fetal outcomes with an aggressive team management approach, early delivery, and detailed postpartum care.15Caring for obstetrical patients with PAH requires exquisitely detailed coordination between the critical care, anesthesia, and obstetrical teams. Because of the previously reported high maternal mortality rates, most standards for this scenario have been derived from case reports.15 In this case report, we highlight the clinical course of a patient with a new diagnosis of PAH at 33 weeks’ pregnancy and the critical coordination of nurses, physicians, pharmacists, and other members of the health care team across multiple services to provide the optimal outcome: a healthy mother and child.A 22-year-old African American woman, gravida 1, para 0 at 33 0/7 weeks’ gestation was admitted to the obstetrical service after a brief, witnessed seizure in the hospital at 5 pm. The patient had been visiting her sister and providing support during the sister’s labor and delivery. On evaluation in the emergency department, the patient was awake and alert, blood pressure was 105/65 mm Hg, and heart rate was 84/min. Her initial oxygen saturation shown by pulse oximetry was 95% on room air with a glucose level of 85 mg/dL. Her medical history included a recent diagnosis of asthma and pregnancy-induced diabetes. Medication included daily insulin at night and albuterol inhaler as needed.The initial workup included a ventilation-perfusion scan to rule out pulmonary embolus and Doppler ultrasounds of the lower extremity, both of which yielded normal findings. Electrocardiography showed right ventricular strain with tall R waves in the lateral wall. A transthoracic echocardiogram done the next day revealed a markedly enlarged right ventricle with right ventricular strain and severe pulmonary hypertension (Figure 1). This patient had no thromboembolic disease, no cardiovascular disease or diagnosis, no interstitial lung disease, and was negative for HIV. Her working diagnosis was idiopathic pulmonary hypertension.A recently formed pulmonary hypertension team consisting of an intensivist/pulmonologist, nurse practitioner, clinical pharmacist, clinical nurse specialist, and case manager met with the patient and her family that day. Consent was obtained for emergent catheterization of the right side of the heart with a planned transfer to the intensive care unit after the procedure for continued hemodynamic monitoring and initiation of drug therapy (see Sidebar). Initial PAP systolic/diastolic pressures were 116/47 mm Hg with a mean PAP of 76 mm Hg, normal cardiac output of 4.94 L/min, and a severely elevated pulmonary vascular resistance of 13 Wood units. Treatment with epoprostenol was started at 2 ng/kg per minute (1.5 mL/h) through a dedicated port of the pulmonary artery catheter without a flush solution (Table 1). In addition to checking of vital signs and hemodynamic measurements, assessment of drug effects included signs and symptoms of too little medication (dyspnea, chest pain) versus too much medication (presence of jaw pain, flushing, and dizziness; Figure 2).High-risk obstetrical nurses stayed at the bedside for continuous fetal monitoring and worked in tandem with the critical care nurses to care for both mother and fetus. They also provided a link to maternal fetal medicine services and made sure that neonatology emergency equipment was at the bedside. The pulmonary hypertension team provided “in the moment” education about PAH, along with reference materials, to all care providers. The reference materials included information on epoprostenol administration, including caution signs regarding low pump rate and no flushing for the intravenous infusion pump, storeroom numbers to order intravenous tubing with no flush port, posters for the staff (Figure 2), information on PAH, and phone number contacts of the pulmonary hypertension team.On days 3 to 5, the epoprostenol dosage (Table 2) was gradually increased to 8 ng/kg per minute and the patient’s mean PAP decreased from 76 to 49 mm Hg with a blood pressure of 100/60 mm Hg. On day 5, the pulmonary hypertension team and representatives from maternal fetal medicine, anesthesia, neonatology, nursing, and social work met to discuss goals of care and to decide on a multidisciplinary plan of care. As many subspecialty caregivers were involved, a successful outcome for both patient and baby would require that all caregivers be aware of one another’s goals and plans. What was new in the equation for this high-risk delivery team was the addition of the pulmonary hypertension team.The pulmonary hypertension team’s goal was to initiate epoprostenol to reduce pulmonary artery pressures and maximize the possibility of survival at the time of delivery. In addition, the goal was to limit fluids up to, during, and after delivery. Limiting fluids was important because it was common practice to give fluid boluses for preterm contractions as well as at other times in the high-risk labor unit. Because the team members were familiar with the care plan, it was not uncommon to check with each other daily as to any changes or needs of the patient and to keep each other completely informed. Ongoing education among the team members became an integral part of the daily routine.The care plan (Table 3) developed for the patient established a goal of maintaining pregnancy until 36 weeks. At that time, the goal was to induce a vaginal delivery with very little pushing, so as to avoid the exponentially increasing maternal blood volume that occurs during the last 4 weeks of gestation. A percutaneously inserted central catheter was placed, the pulmonary artery catheter was removed, and the patient was transferred to the high-risk antepartum unit.In the next 3 weeks, the epoprostenol dosage was increased by increments of 2 ng/kg per minute up to 36 ng/kg per minute, depending on the patient’s tolerance (factors considered included ensuring patient’s systolic blood pressure exceeded 90 mm Hg, patient’s weight, and patient’s complaints of the drug’s effects). The patient was receiving enoxaparin (Lovenox), which has a half-life of 4.5 to 7 hours, for prophylaxis of deep vein thrombosis. A transition to heparin was planned because heparin has a shorter half-life of 1 to 2 hours, which enables quick titration before delivery. Drug authorization for epoprostenol was obtained after emergent initiation including insurance approval; patient and family teaching was initiated by the specialized pharmacy that would provide the medication as an outpatient. Because of the prohibitive costs of medication therapies for PAH, with drug costs that can exceed $100 000 annually, authorization is mandatory. An additional team meeting took place to finalize the plan of care for delivery and postpartum management.On day 26, the patient was transferred to the intensive care unit for elective vaginal Foley bulb induction and early epidural placement. In addition, an arterial catheter was inserted and an introducer was placed in preparation for fluid management and hemodynamic monitoring after delivery.On day 27, an oxytocin (Pitocin) infusion was started after cervical dilation, and when fully dilated, the patient was taken to a large operating room. After 5 instructed half-breath, half-duration pushes and the use of forceps, a healthy 4 lb, 10 oz (2120 g) baby girl was delivered with Apgar scores of 8/9. The patient tolerated the birth well and was subsequently transferred to the intensive care unit for closer monitoring and aggressive diuresis because of the severe risk of cardiac failure due to fluid reequilibration intravascularly after delivery. A pulmonary artery catheter was not required. Epoprostenol dosage remained at 36 ng/kg per minute, and furosemide (Lasix) was initiated with a goal of urine output of 200 mL/h or greater or 10 L total in the next 3 days.On day 28 or postpartum day 1, the epoprostenol dosage remained unchanged and the patient’s diuresis was proceeding per the initial output goal set. The patient began pumping breast milk and breast-feeding her newborn every other feeding. The infant experienced no untoward effects from the epoprostenol or other medications.On postpartum day 3, the epoprostenol rate was adjusted to the new postdelivery body weight and metolazone (Zaroxolyn) was added to enhance diuresis on day 30. The patient was now 7 L negative with stable vital signs.On postpartum days 5 through 9, the patient experienced complications of vaginal bleeding that requiring blood transfusions and vaginal packing. This procedure was done with the patient under moderate sedation in the intensive care unit to avoid the complications and risk of general anesthesia with PAH. Furosemide (Lasix) was discontinued at this time because of mild hypotension; the epoprostenol dosage was unchanged. The patient later became febrile with continued hypotension of 76/41 mm Hg and an oxygen saturation of 77% on room air shown by pulse oximetry. The vaginal packing was then removed as the source of infection with no further bleeding. She was treated with oxygen and the antibiotics cefepime (Maxipime) and vancomycin (Vancocin). Her blood pressure then stabilized, with systolic pressure exceeding 95 mm Hg.The patient was transferred to the pulmonary step-down unit on postpartum day 10. The unit’s staff regularly cared for patients with PAH and was knowledgeable about the disease and therapies. The baby roomed in with the patient and was cared for by the baby’s father. A Hickman catheter was placed for discharge and coumadin (Warfarin) was started for long-term anticoagulation therapy. In addition, medroxyprogesterone (Depo-Provera) was initiated for intermediate birth control.The patient and her healthy newborn were discharged to home on postpartum day 13 or hospital day 40, with the patient receiving epoprostenol at 43 ng/kg per minute through her Hickman catheter. Other discharge medications included warfarin and digoxin. Anticoagulation improves survival, and it is recommended for all patients with idiopathic PAH.4,6 Outpatient follow-up included appointments with her pulmonologist and postpartum care with her obstetrician for long-term contraception. All women with known PAH are strongly counseled to use birth control, as the risk of maternal death and premature delivery with PAH is high.6 In addition, the PAH home care nurse will continue to follow up at home, teaching the patient and her family as well as educating the local emergency medical service about PAH and epoprostenol infusions.Both identification and management of this patient with her new diagnosis of PAH at 33 weeks’ gestation presented a challenge that necessitated immediate actions and coordination of care across multiple services to ensure a successful outcome for both the mother and her baby. There is little expertise with PAH and pregnancy because of both the low incidence and the lack of research in this population; case reports have been published. Delivery of the infant does not decrease the risk to the patient who has PAH. The postpartum period carries the greatest risk of maternal mortality because of the acute increase in the pulmonary vascular resistance postpartum, along with right ventricular decompensation due to physiological fluid shifts that occur during the first 14 days postpartum.6,7,13,16Coordination between the multiple disciplines was crucial. The 2 team meetings provided a forum for all the providers to ask questions and detail not only the delivery, but the time when the maternal risk is greatest, the postpartum period. The care plan included medication use during the antenatal period, labor and delivery plan, and the crucial hemodynamic management after delivery. The team reached consensus on the overall goal for the patient and infant, the role of each team member, and the planned interventions to reduce any potential complication.It is important for health care systems to have access to a dedicated pulmonary hypertension team as a resource to guide practitioners in both diagnosis and therapy of PAH. This patient needed an emergent infusion of epoprostenol on a late Friday afternoon with caregivers who had little knowledge or expertise in its administration. Hemodynamic monitoring was required to observe the initiation and effects of the drug with 24-hour access to the pulmonary hypertension team. The team was not only used for management but for daily bedside education and monitoring.A binder was used to store all education materials and kept with the patient’s chart. The binder included general information on PAH, detailed information about epoprostenol infusion, and detailed patient-specific charts on titration provided by the pharmacy. Few drugs are delivered in nanograms per kilogram per minute and the staff was unfamiliar with the calculation. All titration orders were provided by the pulmonary hypertension team. Institutions without access to an in-house pulmonary hypertension team can access alternative resources by calling designated pulmonary hypertension centers or by using the expertise of the pharmacists and nurses who work with these medication therapies at the specialized pharmacies that distribute these medications.Patient education was also crucial and had to be adapted to the needs of the patient and her family. Education began on day 1 and continued throughout the patient’s hospitalization. The patient was included in her daily evaluations and management, which allowed her to make knowledgeable contributions to her care. She was discharged after demonstrating that she could manage the 24-hour responsibility of a continuous intravenous infusion, coping with her new PAH diagnosis, and, last but not least, the care of her daughter.The patient had initially begun and wanted to breastfeed, but her postdelivery course of vaginal bleeding and infection made this difficult and the baby was converted to bottle feeding. No research has been published that supports or does not support breastfeeding while being treated with epoprostenol, and additional research is needed. Peer-to-peer networking between PAH physicians and examination of the properties of epoprostenol supported this decision. Although the baby had no untoward effects during the brief period of breast feeding; unfortunately the baby had to be switched to bottle feeding because of the patient’s complications of bleeding and sepsis.This case illustrates the importance of the management of all patients with PAH by team members with experience in the specialized care of these patients. In addition, it is crucial to have coordination, leadership, and planning throughout the health care system in order to optimize the patient’s outcome in the difficult scenario of pregnancy and PAH.
No takes yet. Share an insight, caveat, or question.
Seckel et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: